Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natesto for Hypogonadism and Spermatogenesis Maintenance
NCT05381831Phase 4Completed
- Sponsor
- University of Florida
- Start
- Jun 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of natesto in Hypogonadism, sponsored by University of Florida. Primary endpoint: Total Motile Sperm Count at 26 weeks. Started Jun 2022; status: completed.
02
Drugs
natesto
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on NCT05381831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05381831.